101
Lam et al.
Descriptive analysis of the efficacy and safety of radiosynoviorthesis in a Singaporean tertiary hospital
102
Iakovou et al.
Erbium-169 Radiosynoviorthesis Following Surgery for Ankle pigmented villonodular synovitis-PVNS: Long-Term Outcomes
from a Rare Disease Cohort with 63-Month Median Follow-Up
103
Iakovou et al.
Long-Term Outcomes of Adjuvant Erbium-169 Radiosynoviorthesis for Ankle Pigmented Villonodular Synovitis in Young Athletes: A 46-Month Follow-Up Study
104
Koutsikos et al.
Factors affecting 48hr 131I Residual Activity in Radioactive therapy (RAIT) in patients with well-differentiated thyroid cancer (WDTC)
105
Tsangaridi et al.
From Conventional Care to Connected Care: Empowering Thyroid Cancer Patients Through a Smart App That Actually Makes a Difference.
106
Tsangaridi et al.
Looking Beyond the Gland: Radiomics Redefines Response Prediction in Differentiated Thyroid Cancer.
107
Hertz
Dr Saul Hertz RAI : The Birth of ZTHeranostics
108
Biswas et al.
Evaluating recurrent thyroid carcinoma: Pivotal role of high resolution ultrasonography where 131 I-whole body scan is negative
and not significantly raising thyroglobulin (Tg) level
109
Yang et al.
Radio-Iodine labeled anti-GD2 antibody (APN311) as a theranostic radiopharmaceutical for neuroblastoma xenograft tumors
110
Chatti et al.
Therapeutic Value of 18F-FDG PET/CT in Monitoring Cutaneous and Mucosal Melanoma: Preliminary Experience from Sousse
111
Chatti et al.
Clinical Value and Limitations of 18F-FDG PET/CT in Neuroendocrine Tumors: A Tunisian experience
112
Skouridi et al.
Preliminary Validation of Q. Thera AI Dosimetry Application for mCRPC Patients Undergoing PSMA-Targeted Lu-177 Therapy
201
Paschali et al.
Can we predict response in PSMA radioligand therapy? A single center retrospective study assessing PSMA imaging phenotype parameters-
in the theranostic setting- with treatment response
202
dos Santos Loureiro et al.
Retrospective analysis of metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617 Radioligand therapy in Uruguay
203
Jubilee et al.
Manufacture and characterisation of radiolabelled pH-sensitive liposomes for the delivery of docetaxel in Prostate Cancer
204
Dureja et al.
Response-Adapted PSMA Radioligand Therapy Without Dosimetry: A Feasible Model for Low-Resource Settings
205
Prisacariu et al.
Vascular Flip-Flop: Theranostic Transition In Oncocytic Thyroid Carcinoma
206
Lim et al.
The combination of 225Ac-DOTA-rituximab and lanatoside C augmented cytotoxicity in lymphoma cells
207
Y S et al.
A Retrospective Analysis of Lutetium-177 PRRT in Patients with Metastatic Neuroendocrine Tumors:
Study to guide to decrease 200mci per cycle to 100mCi per cycle of Lu-177 DOTATATE therapy
208
Dash et al.
Feasibility and Safety of 161Tb-FAP2268 Peptide Targeted Radionuclide Therapy in Solid Tumors: Preliminary Clinical Insight from India
209
Di Santo et al.
Prognostic implication of [¹⁸F]FDG PET and its Metabolic Changes in Patients with Advanced Metastatic Neuroendocrine
Tumors Undergoing Rechallenge PRRT: Final Results from a Multicenter 10-Years Survival
210
Sahmim et al.
How to secure therapy ? « process mapping » could be the game-changer
211
Sergieva et al.
68Ga-FAPI PET Imaging in Oncology
212
Atiya et al.
Role of 68 Ga DOTA-TATE PET/CT in the evaluation of gastroenteropancreatic neuroendocrinal tumors and its impact on the clinical outcome
The recipient will receive complimentary registration for the 14th World Congress of the World Federation of Nuclear Medicine and Biology, taking place from 13 to 16 February 2026 in Cartagena, Colombia. The award also includes an invitation to the Congress’s closing ceremony and a $1,000 travel grant to support attendance.
Eligible abstracts should focus on Theragnostics and Radiopharmaceutical Therapy, aligning with the core theme of the International Conference on Radiopharmaceutical Therapy (ICRT2025).
This award will be presented for a poster focused on research in Radioligand Therapy. It includes a €2,000 travel grant to attend the 8th Theranostics World Congress in Cape Town, South Africa, from 29 January to 1 February 2026, along with a congress entry badge.